Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
NCT ID: NCT01234129
Last Updated: 2010-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
320 participants
OBSERVATIONAL
2002-06-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
zoledronic acid or not zoledronic acid
patients with multiple myeloma will be treated with cytoreductive therapy following by zoledronic acid or not.
No interventions assigned to this group
zoledronic acid or not zoledronic acid
patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid
zoledronic acid
zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
zoledronic acid
Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid
zoledronic acid
zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
zoledronic acid
zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
\-
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Mexicano del Seguro Social
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mexican Institute of Social Security
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Agustin Aviles, MD
Role: PRINCIPAL_INVESTIGATOR
Instituto Mexicano del Seguro Social
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tertiary reference oncology center
Mexico City, Mexico City, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
kitty2
Identifier Type: OTHER
Identifier Source: secondary_id
kitty1
Identifier Type: -
Identifier Source: org_study_id